![Tenfoday EM (Tenofovir + Emtricitabine)](https://mhp.ooo/files/products/img-20240614-wa0012.200x200.jpg)
![Baracavir 0.5 (Entecavir)](https://mhp.ooo/files/products/5701739a-1086-46ef-829e-6003dd6a4745.200x200.jpg)
![Starquin 200 (Hydroxychloroquine)](https://mhp.ooo/files/products/2ac40c97-8585-4a46-a257-2544ea78c171.200x200.jpg)
Hepatitis C
Hepatitis C is a viral pathology that is transmitted mainly through the blood and poses a serious danger to human health. The liver suffers the most from hepatitis C. The peculiarity of this disease is its asymptomatic course: people often do not suspect that they are sick.
Until recently, hepatitis C was treated with ribavirin and interferon. These drugs were not always effective and caused various adverse reactions. The situation changed with the invention of new antiviral drugs.
To date, the most effective treatment is considered to be with the use of two drugs - sofosbuvir and daclatasvir. According to the current EASL guidelines, these agents are prescribed for all genotypes of the virus. More than 23,000 patients from Russia who took these drugs were convinced of their effectiveness.
Properties of drugs
Sofosbuvir is an antiviral drug that has a direct effect on the virus. It is the main component in the treatment of adult patients with chronic hepatitis C. The peculiarity of sofosbuvir is that it acts only on the virus and blocks its reproduction in the body. The drug is used in combination with daclatasvir, ledipasvir, simeprevir, ribavirin and other medicines.
Daclatasvir inhibits the protein compounds of the NS5A virus and prevents the spread of infection in the body. As a result, it is possible to block the infection of healthy cells. Daclatasvir is not intended for monotherapy. It is included in complex treatment regimens and is used in conjunction with other antiviral drugs: ribavirin, asunaprevir, sofosbuvir, peginterferon, etc.
Benefits of Daclatasvir and Sofosbuvir
Numerous patient reviews indicate the high efficacy of the combination of daclatasvir and sofosbuvir. In addition, these drugs have virtually no adverse reactions. Complex therapy with the use of these medicines allows the patient to lead a normal life and does not affect the blood composition.
In addition, sofosbuvir and daclatasvir have the following benefits:
- A small number of contraindications: the main limitation is associated with intolerance to the components of the drugs.
- Good tolerance: negative reactions are rare.
- High efficiency: in most cases, patients are completely cured.
- Fast result: the effect is noticeable already after a few weeks from the start of treatment.
Indian generics for hepatitis C
Original drugs have a very high price, which is why most patients cannot buy them.
The emergence of generics from India has given people of any income level a chance to recover. Generic is an analogue, in composition and effectiveness, identical to the original drug. However, the cost of the analogue is much lower than the original.
The production of modern medicines is closely monitored by drug developers. In addition, regulatory authorities check the compliance of the generic with current quality and safety standards.
Before buying medicines, you need to consult your doctor. Only a specialist will be able to correctly determine the dosage and duration of treatment.
Virus genotype |
Interferon therapy |
Cirrhosis of the liver |
Sofosbuvir Daklatasvir |
Sofosbuvir Ledipasvir |
Sofosbuvir Velpatasvir |
Grazoprevir Elbasvir |
Glecaprevir Pibrentasvir |
Sofosbuvir Velpatasvir Voxilaprevir |
Genotype 1 |
Not |
Yes |
24 weeks |
24 weeks |
24 weeks |
- |
12 weeks |
12 weeks |
Not |
12 weeks |
12 weeks |
12 weeks |
12 weeks |
8 weeks |
8 weeks |
||
Yes |
|
24 weeks |
24 weeks |
24 weeks |
- |
- |
- |
|
Genotype 2 |
Not |
Yes |
24 weeks |
Not effective |
24 weeks |
Not effective |
12 weeks |
12 weeks |
Not |
12 weeks |
12 weeks |
8 weeks |
8 weeks |
||||
Yes |
|
24 weeks |
24 weeks |
- |
- |
|||
Genotype 3 |
Not |
Yes |
24 weeks |
Not effective |
24 weeks |
- |
12 weeks |
8 weeks |
Not |
12 weeks |
12 weeks |
12 weeks (in conjunction with sofosbuvir) |
8 weeks |
8 weeks |
|||
Yes |
|
24 weeks |
24 weeks |
- |
- |
- |
||
Genotype 4 |
Not |
Yes |
24 weeks |
24 weeks |
24 weeks |
- |
12 weeks |
12 weeks |
Not |
12 weeks |
12 weeks |
12 weeks |
12 weeks |
8 weeks |
8 weeks |
||
Yes |
|
24 weeks |
24 weeks |
24 weeks |
- |
- |
- |
|
Genotype 5-6 |
Not |
Yes |
24 weeks |
24 weeks |
24 weeks |
Not effective |
12 weeks |
12 weeks |
Not |
12 weeks |
12 weeks |
12 weeks |
8 weeks |
8 weeks |
|||
Yes |
|
24 weeks |
24 weeks |
24 weeks |
- |
- |